Aileron Therapeutics, Inc, based in Watertown, MA, is a biopharmaceutical company focused on developing innovative therapies for orphan pulmonary and fibrosis conditions. With the recent acquisition of Lung Therapeutics and a concurrent $18M private investment, Aileron is well-positioned to advance its pipeline of first-in-class medicines to address significant unmet medical needs in these diseases.
The company's lead clinical programs include LTI-03, a pioneering compound for idiopathic pulmonary fibrosis (IPF), and LTI-01, a first-in-class treatment for loculated pleural effusion (LPE). Aileron's management team, led by CEO Manuel C. Aivado, M.D., Ph.D, brings extensive experience in clinical development and pharmacovigilance, ensuring the company's commitment to delivering better treatment options for patients with life-threatening pulmonary conditions.
Generated from the website
